Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
acneiform eruption
cutaneous toxicity
molecularly targeted agents
papulopustular eruption
target therapy
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
08
02
2023
received:
24
11
2022
accepted:
22
02
2023
medline:
27
7
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
Various biologic agents targeting specific molecules present new treatment options for various tumors. Acneiform eruption is a very common skin reaction to these agents. Although not life-threatening, acneiform eruption can affect patients' emotional and social lives. In very exceptional cases, it can lead to cancer therapy interruption. The aim of this study was to review the incidence rate, clinical characteristics, pathogenesis, and current management of acneiform eruption induced by molecularly targeted agents. This review was carried out through PubMed, Embase, and Cochrane searching terms 'acneiform eruption', 'papulopustular eruption' or 'acne-like rash' and 'skin toxicity', 'cutaneous toxicity', 'skin reactions', 'dermatological toxicities', 'target therapy,' or 'drug therapy'. Of the 73 articles matched our search terms, 61 were original articles and 12 were case reports or case series. Acneiform eruption is most commonly observed in patients treated with epidermal growth factor receptor inhibitors and mitogen-activated protein kinase inhibitors. Typical lesions consist of erythematous papules and pustules without comedones, accompanying with burning, pruritus, or xerosis. The pathogenesis involves inflammation and abnormalities of the follicular epithelium, where a disorder in EGFR signaling plays a key role. The treatment of acneiform eruption depends on the severity of the rash. Early recognition and effective management of this cutaneous adverse reaction can prevent unnecessary reduction and discontinuation of drug use and improve patient survival and quality of life. Close collaboration between oncologists and dermatologists is important to optimize therapy and improve patient survival.
Sections du résumé
BACKGROUND
BACKGROUND
Various biologic agents targeting specific molecules present new treatment options for various tumors. Acneiform eruption is a very common skin reaction to these agents. Although not life-threatening, acneiform eruption can affect patients' emotional and social lives. In very exceptional cases, it can lead to cancer therapy interruption.
AIMS
OBJECTIVE
The aim of this study was to review the incidence rate, clinical characteristics, pathogenesis, and current management of acneiform eruption induced by molecularly targeted agents.
METHODS
METHODS
This review was carried out through PubMed, Embase, and Cochrane searching terms 'acneiform eruption', 'papulopustular eruption' or 'acne-like rash' and 'skin toxicity', 'cutaneous toxicity', 'skin reactions', 'dermatological toxicities', 'target therapy,' or 'drug therapy'.
RESULTS
RESULTS
Of the 73 articles matched our search terms, 61 were original articles and 12 were case reports or case series. Acneiform eruption is most commonly observed in patients treated with epidermal growth factor receptor inhibitors and mitogen-activated protein kinase inhibitors. Typical lesions consist of erythematous papules and pustules without comedones, accompanying with burning, pruritus, or xerosis. The pathogenesis involves inflammation and abnormalities of the follicular epithelium, where a disorder in EGFR signaling plays a key role. The treatment of acneiform eruption depends on the severity of the rash.
CONCLUSIONS
CONCLUSIONS
Early recognition and effective management of this cutaneous adverse reaction can prevent unnecessary reduction and discontinuation of drug use and improve patient survival and quality of life. Close collaboration between oncologists and dermatologists is important to optimize therapy and improve patient survival.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2150-2157Informations de copyright
© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Nikolaou V, Voudouri D, Tsironis G, et al. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients. Support Care Cancer. 2019;27(12):4535-4542.
Hayashi H, Iihara H, Hirose C, et al. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. Lung Cancer. 2019;134:1-6.
Grávalos C, Sanmartín O, Gúrpide A, et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish academy of dermatology and venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2019;21(5):556-571.
Clabbers JMK, Boers-Doets CB, Gelderblom H, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24(2):513-521.
Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22(3):524-535.
Park JH, Choi Y, Kim HJ, et al. Duration of Oral antibiotics Administration for Cetuximab-Induced Acneiform Eruption. Dermatology. 2020;237(3):457-463.
Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390-5396.
Fernández-Mateos J, Seijas-Tamayo R, Mesía R, et al. Spanish head and neck cancer cooperative group (TTCC). Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Oral Oncol. 2016;63:38-43.
Sheu J, Hawryluk EB, Litsas G, Thakuria M, LeBoeuf NR. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer. 2015;15(1):e77-e81. doi:10.1016/j.clbc.2014.09.003
Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172(1):239-243.
Park K, Ommori R, Imoto K, Asada H. Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by Staphylococcus epidermidis. J Dermatol Sci. 2014;75(2):94-99.
Song H, Zhong CS, Kieran MW, Chi SN, Wright KD, Huang JT. Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study. Pediatr Blood Cancer. 2019;66(6):e27682. doi:10.1002/pbc.27682
Paul T, Schumann C, Rüdiger S, et al. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer. 2014;50(11):1855-1863.
Park JH, Yoon D, Lee J, et al. Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center. J Dermatol. 2021;48(7):979-988.
Keiser MF, Patel AB, Altan M. Cutaneous toxicities in lung cancer patients on immune checkpoint inhibitor therapy. Clin Lung Cancer. 2021;22(3):195-200.
Dika E, Ravaioli GM, Fanti PA, et al. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. Eur J Dermatol. 2017;27(3):266-270.
Da M, Shi M, Yan Q, et al. Skin adverse reactions to afatinib and their correlation with anti-lung cancer efficacy. Chinese Journal of Dermatology. 2021;1:64-67.
Yalici-Armagan B, Ayanoglu BT, Demirdag HG. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study. Cutan Ocul Toxicol. 2019;38(3):261-266.
Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72(3-4):152-159.
Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):347-354.
Chen P, Chen F, Zhou B. The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis. Cutan Ocul Toxicol. 2019;38(2):105-111.
Lacroix JP, Wang B. Prospective case series of cutaneous adverse effects associated with Dabrafenib and Trametinib. J Cutan Med Surg. 2017;21(1):54-59.
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.
Fleta-Asín B, Vañó-Galván S, Ledo-Rodríguez A, Truchuelo-Díez M, Jaén-Olasolo P. Facial acneiform rash associated with sorafenib. Dermatol Online J. 2009;15(4):7.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
Song L, Jing H, Mao L. Clinical analysis of seven cases of cutaneous adverse reactions due to epidermal growth factor receptor-tyrosine kinase inhibitor. Chinese Journal of Dermatovenereology. 2020;34(12):1394-1399.
Nakahara T, Moroi Y, Takayama K, et al. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. Onco Targets Ther. 2015;8:259-263.
Boull CL, Gardeen S, Abdali T, et al. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multi-center study. J Am Acad Dermatol. 2020;84(6):1554-1561.
Gisondi P, Geat D, Mattiucci A, Lombardo F, Santo A, Girolomoni G. Incidence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small-cell lung cancer. Dermatology. 2021;237(6):929-933.
Welborn M, Kubicki SL, Garg N, Patel AB. Twelve cases of acneiform eruptions while on anti-CTLA4 therapy. Support Care Cancer. 2020;28(6):2499-2502.
He Y, Xu H, Li C, et al. Nicastrin/miR-30a-3p/RAB31 Axis regulates keratinocyte differentiation by impairing EGFR signaling in familial acne Inversa. J Invest Dermatol. 2019;139(1):124-134.
Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20(1):110-124.
Oh JH, Hur W, Li N, Jo SJ. Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes. Exp Dermatol. 2022;31(6):918-927.
Satoh TK, Mellett M, Meier-Schiesser B, et al. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130(3):1417-1430.
Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55(4):250-254.
Caruana M, Hatami A, Marcoux D, Perreault S, McCuaig CC. Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib. JAAD Case Rep. 2020;6(10):1056-1058.
Bostan E, Akdogan N. Acne inversa-like lesions and acneiform eruption associated with vemurafenib and cobimetinib used for advanced melanoma. J Cosmet Dermatol. 2020;20(6):1944-1945.
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol. 2020;38(6):660-678.
Agirgol S, Çaytemel C, Pilanci KN. Dermatological side effects of targeted antineoplastic therapies: a prospective study. Cutan Ocul Toxicol. 2020;39(4):380-384.
Lee JH, Ju HJ, Kwon HS, et al. Efficacy of topical epidermal growth factor cream for patients with epidermal growth factor receptor inhibitor-induced acneiform eruption: a randomized controlled trial. Br J Dermatol. 2020;182(1):219-221.
Kim YS, Ji JH, Oh SY, et al. A randomized controlled trial of epidermal growth factor ointment for treating epidermal growth factor receptor inhibitor-induced skin toxicities. Oncologist. 2020 Jan;25(1):e186-e193. doi:10.1634/theoncologist.2019-0221
Shacham Shmueli E, Geva R, Yarom N, et al. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. Support Care Cancer. 2019;27(8):3027-3033.
Pugliese SB, Neal JW, Kwong BY. Management of Dermatologic Complications of lung cancer therapies. Curr Treat Options Oncol. 2015;16(10):50.
Pinta F, Ponzetti A, Spadi R, et al. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13(1):62-67.
Karadag AS, Aslan Kayıran M, Wu CY, Chen W, Parish LC. Antibiotic resistance in acne: changes, consequences and concerns. J Eur Acad Dermatol Venereol. 2021;35(1):73-78.
Bardazzi F, Savoia F, Parente G, et al. Azithromycin: a new therapeutical strategy for acne in adolescents. Dermatol Online J. 2007;13(4):4.
Costello CM, Hill HE, Brumfiel CM, Yang YW, Swanson DL. Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions. J Am Acad Dermatol. 2021;84(3):840-841.
Bierbrier R, Lam M, Pehr K. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors. Dermatol Ther. 2022;35(5):e15412. doi:10.1111/dth.15412
Rothschild SI, Betticher D, Zenhäusern R, et al. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer Chemother Pharmacol. 2019;84(4):881-889.